Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Nov 8

PMID 39513892

Authors

Damayanti Das Ghosh

Hannah McDonald

Rajeswari Dutta

Keerthana Krishnan

Jaya Thilakan

Manash K Paul

Neha Arya

Mahadev Rao

Vivek M Rangnekar

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) has established predictive biomarkers that enable decisions on treatment regimens for many patients. However, resistance to therapy is widespread. It is therefore essential to have a panel of molecular biomarkers that may help overcome therapy resistance and prevent adverse effects of treatment. We performed in silico analysis of NSCLC prognostic indicators, separately for adenocarcinomas and squamous carcinomas, by using The Cancer Genome Atlas (TCGA) and non-TCGA data sources in cBioPortal as well as UALCAN. This review describes lung cancer biology, elaborating on the key genetic alterations and specific genes responsible for resistance to conventional treatments. Importantly, we examined the mechanisms associated with resistance to immune checkpoint inhibitors. Our analysis indicated that a robust prognostic biomarker was lacking for NSCLC, especially for squamous cell carcinomas. In this work, our screening uncovered previously unidentified prognostic gene expression indicators, namely, , homologs, and for adenocarcinoma, and and for squamous cell carcinoma. It was further observed that overexpression of these genes was associated with poor prognosis. Additionally, homolog and unexpectedly harbored copy number amplifications. In conclusion, this study elucidated novel prognostic indicators for NSCLC that may serve as targets to overcome therapy resistance toward improved patient outcomes.

References

Shang Z, Niu X, Zhang K, Qiao Z, Liu S, Jiang X . FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. J Mol Med (Berl). 2019; 97(12):1657-1668. DOI: 10.1007/s00109-019-01848-z. View

Villa E, Proics E, Rubio-Patino C, Obba S, Zunino B, Bossowski J . Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells. Cell Rep. 2017; 20(12):2846-2859. DOI: 10.1016/j.celrep.2017.08.087. View

Shi R, Jiao Z, Yu A, Wang T . Long noncoding antisense RNA FAM83A-AS1 promotes lung cancer cell progression by increasing FAM83A. J Cell Biochem. 2019; 120(6):10505-10512. PMC: 6590457. DOI: 10.1002/jcb.28336. View

Bartel C, Parameswaran N, Cipriano R, Jackson M . FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget. 2016; 7(32):52597-52612. PMC: 5239576. DOI: 10.18632/oncotarget.9544. View

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Brummel K, Eerkens A, de Bruyn M, Nijman H . Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2022; 128(3):451-458. PMC: 9938191. DOI: 10.1038/s41416-022-02119-4. View

Mazieres J, Peters S, Lepage B, Cortot A, Barlesi F, Beau-Faller M . Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31(16):1997-2003. DOI: 10.1200/JCO.2012.45.6095. View

Lu S . Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther. 2019; 12:1521-1538. PMC: 6390854. DOI: 10.2147/OTT.S188296. View

Feng C, Feng M, Gao Y, Zhao X, Peng C, Yang X . Clinicopathologic Significance of Intestinal-type Molecules' Expression and Different EGFR Gene Status in Pulmonary Adenocarcinoma. Appl Immunohistochem Mol Morphol. 2018; 27(5):364-372. DOI: 10.1097/PAI.0000000000000632. View

10.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

11.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

12.

Moosavi F, Giovannetti E, Saso L, Firuzi O . HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019; 56(8):533-566. DOI: 10.1080/10408363.2019.1653821. View

13.

Pathak N, Chitikela S, Malik P . Recent advances in lung cancer genomics: Application in targeted therapy. Adv Genet. 2021; 108:201-275. DOI: 10.1016/bs.adgen.2021.08.004. View

14.

Yamaura T, Muto S, Mine H, Takagi H, Watanabe M, Ozaki Y . Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma. Oncol Lett. 2020; 19(6):4169-4176. PMC: 7204631. DOI: 10.3892/ol.2020.11524. View

15.

Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T . The artificial intelligence and machine learning in lung cancer immunotherapy. J Hematol Oncol. 2023; 16(1):55. PMC: 10207827. DOI: 10.1186/s13045-023-01456-y. View

16.

Bencze E, Bogos K, Kohanka A, Bathory-Fulop L, Sarosi V, Csernak E . EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits. Pathol Oncol Res. 2022; 28:1610607. PMC: 9579289. DOI: 10.3389/pore.2022.1610607. View

17.

Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper W . An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. J Clin Med. 2018; 7(6). PMC: 6025105. DOI: 10.3390/jcm7060153. View

18.

Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C . Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer. 2017; 140(12):2805-2819. DOI: 10.1002/ijc.30691. View

19.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

20.

Maruhashi T, Sugiura D, Okazaki I, Shimizu K, Maeda T, Ikubo J . Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022; 55(5):912-924.e8. DOI: 10.1016/j.immuni.2022.03.013. View